Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot (ACROBAT Evolve)

Trial Profile

A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot (ACROBAT Evolve)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRN-00808 (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Acronyms ACROBAT EVOLVE
  • Sponsors Crinetics Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2019 According to a Crinetics Pharmaceuticals media release, the first patient has been dosed in this trial.
    • 08 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03792555)
    • 01 Jan 2019 Planned primary completion date changed to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top